Gefitinib APIs by Loncom Pharma are designed to inhibit the tyrosine kinase activity associated with EGFR, providing a targeted therapy for patients with certain types of non-small cell lung cancers, and showcasing the company's innovative approach to oncology.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
